Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. (20th October 2005)

• Record Type: Journal Article
• Authors: Furst, D E; Breedveld, F C; Kalden, J R; Smolen, J S; Burmester, G R; Bijlsma, J W J; Dougados, M; Emery, P; Keystone, E C; Klareskog, L; Mease, P J
• Is Part Of: Annals of the rheumatic diseases. Volume 64(2005)Supplement 4
• Page Start: iv2
• Page End: iv14
• Publication Date: 2005-10-20
• Subjects: aCL, anticardiolipin antibodies -- ACR, American College of Rheumatology -- ANA, antinuclear antibodies -- AS, ankylosing spondylitis -- ASCVD, atherosclerotic cardiovascular disease -- CHF, congestive heart failure -- DAS, Disease Activity Score -- DMARD, disease modifying antirheumatic drug -- HAQ-DI, Health Assessment Questionnaire disability index -- IL-1(ra), interleukin-1 (receptor antagonist) -- MTX, methotrexate -- PsA, psoriatic arthritis -- RA, rheumatoid arthritis -- SDAI, Simple Disease Activity Index -- SF-36, Medical Outcome Survey Short Form 36 -- TNF, tumour necrosis factor -- VAS, visual analogue scale; TNF blocking -- RA -- psoriatic arthritis -- ankylosing spondylitis -- inflammation -- immunity -- IL-1ra -- guideline; Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/ard.2005.044941
• Languages: English
• ISSNs: 0003-4967